Regimen Reference Order GYNE – PACLitaxel + CARBOplatin Intraperitoneal (IP)

ARIA: GYNE - [PACL+CARBO (Intraperitoneal)]

Planned Course: Every 21 days for up to 6 cycles

Indication for Use: Ovarian Cancer Adjuvant, Optimally debulked

CVAD: At Provider's Discretion

Alert: Intraperitoneal Catheter Required

Proceed	with	treatment if:
---------	------	---------------

Cycle 1

<u>Day 1</u>

• ANC equal to or greater than 1.5×10^9 /L AND Platelets equal to or greater than 100×10^9 /L Day 8

• Blood work at provider's discretion: not required to proceed with treatment

Cycle 2 and Onwards

<u>Day 1</u>

• ANC equal to or greater than 1.5×10^9 /L AND Platelets equal to or greater than 75 $\times 10^9$ /L Day 8

• Blood work at provider's discretion: not required to proceed with treatment

Contact Physician if parameters not met

SEQUENCE OF MEDICATION ADMINISTRATION

Drug	Dose	CCMB Administration Guideline
------	------	-------------------------------

Treatment Regimen – GYNE – PACLitaxel + CARBOplatin Intraperitoneal (IP)

Drug	Dose	CCMB Administration Guideline
Day 1		
Establish IV primary	solution 500 mL of: no	ormal saline
cetirizine	20 mg	Orally 1 hour prior to PACLitaxel
aprepitant	125 mg	Orally 1 hour pre-chemotherapy
ondansetron	16 mg	Orally 30 minutes pre-chemotherapy
dexamethasone	20 mg	IV in normal saline 50 mL over 15 minutes <u>1 hour</u> prior to PACLitaxel *Nursing Alert: PACLitaxel starts 1 hour after completion of dexamethasone infusion

Page 1 of 4

DA CLitaval	175 mg/m ²	Introveneus (N/) in normal soling E00 mL over 3 hours, following the
PACLitaxel	175 mg/m ²	Intravenous (IV) in normal saline 500 mL over 3 hours, following the administration rates below:
		Administer at 100 mL/hour for 15 minutes, then
		Administer remaining volume over 2 hours and 45 minutes
		Use non-DEHP bags and non-DEHP administration sets with 0.2 or 0.22 micron filter
		*Nursing Alert: Gently invert bag 8 to 10 times immediately prior to administration of PACLitaxel to evenly distribute the drug
	attempt to empty blade	
Establish IP primary	solution 1000 mL of: nor	mal saline
CARBOplatin	AUC 6 mg/mL.min;	Intraperitoneal (IP) in normal saline 1000 mL infused as rapidly as possible by gravity
	maximum dose 900 mg	
	(see table below)	
normal saline	1000 mL	Intraperitoneal (IP) infused as rapidly as possible by gravity immediately following infusion of IP CARBOplatin
		*Nursing Alert: Patient to rotate body position every 15 minutes
Day 8		
Establish IV primary	solution 500 mL of: norm	nal saline
cetirizine	20 mg	Orally 1 hour prior to PACLitaxel
dexamethasone	20 mg	IV in normal saline 50 mL over 15 minutes <u>1 hour</u> prior to PACLitaxel *Nursing Alert: PACLitaxel starts 1 hour after completion of dexamethasone infusion
Encourage patient to	attempt to empty blade	ler and bowel
Establish IP primary	solution 1000 mL of: nor	mal saline
Wait 1 hour after co	mpletion of IV pre-medic	ation(s) before starting PACLitaxel
PACLitaxel	60 mg/m ²	Intraperitoneal (IP) in normal saline 1000 mL infused as rapidly as possible by gravity
		Use non-DEHP bags and non-DEHP administration sets with 0.2 or 0.22 micron filter
		*Nursing Alert: Gently invert bag 8 to 10 times immediately prior to administration of PACLitaxel to evenly distribute the drug
normal saline	1000 mL	Intraperitoneal (IP) infused as rapidly as possible by gravity
		immediately following infusion of IP PACLitaxel

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'



REQUIRED MONITORING

All Cycles

Nurse to remain at bedside for the first 15 minutes of intraperitoneal administration. Monitor for signs of unexpected side effects such as acute abdominal pain, edema around port site, dyspnea or fluid leaking from port site and/or vagina

Day 1

- CBC, serum creatinine, electrolytes, liver enzymes and CA-125 levels as per Physician Orders
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and as clinically indicated
- No observation period is required after PACLitaxel administration. Patient can be discharged from treatment room if stable whether they had a reaction or not

Day 8

- CBC and biochemistry as per Physician Orders. Not required to proceed with treatment
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and as • clinically indicated
- No observation period is required after PACLitaxel administration. Patient can be discharged from treatment room if stable whether they had a reaction or not

	Recommer	nded Support Medications
Drug	Dose	CCMB Administration Guideline
aprepitant	80 mg	Orally once daily on Days 2 and 3
dexamethasone	8 mg	Orally once daily on Days 2 and 3
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting


DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Instruct patient to continue taking anti-emetic(s) at home
 - Patient should report to physician or nurse:
 - unusual abdominal pain, 0
 - o expanding waistline between treatments,
 - o fever or chills,
 - shortness of breath
 - 0 nausea and/or vomiting greater than 3 days
 - 0 diarrhea or constipation greater than 3 days
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy



ADDITIONAL INFORMATION

- PACLitaxel may cause progressive, irreversible neuropathy
- Administration site restrictions are in place for intraperitoneal route of administration
- CARBOplatin dose considerations:
 - o CCMB Gynecological DSG uses actual body weight to calculate GFR
 - o CCMB Gynecological DSG uses a maximum CARBOplatin dose of 900 mg for this regimen
 - If calculated CARBOplatin dose differs more than 10% from prescribed CARBOplatin dose, contact the prescriber



AUC = Area Under Curve

The estimated creatinine clearance is based on limited evidence. Sound clinical judgment and interpretation of the estimation are required, because the equation may not be appropriate for some patient populations (for example, acute renal failure).

